BSX: Boston Scientific Corporation - Summary | Jitta

Boston Scientific Corporation

NYSE:BSX

Price
$53.60
Loss Chance
49.5%
4.96JITTA SCORE
56.92%Over Jitta Line
Jitta Ranking
120 / 1,156
1,319 / 5,069
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (59)
Recent Business Performance (73)
Financial Strength (77)
Return to Shareholders (11)
Competitive Advantage (51)
Jitta Signs
Interest Coverage RatioGood
SG&A to SalesDecreasing
Revenue and EarningEarning decline from 2019-2022
Operating MarginInconsistent
Recent Business PerformanceEarning decline 28.15% in the last year
Key Stats
Jitta Score
Jitta Line
4.96
56.92%
2.00
167.96%
Health Care Equipment
2.97
45.36%
5.24
14.48%
5.82
3.32%
COMPANY DESCRIPTION
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.